Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169714 · ClinicalTrials.gov registry record · Phase 1
A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01169714 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT01169714, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is designed to observe the safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 for a duration of 14 days, in healthy adult and healthy elderly.
Interventions
- DRUG 0.1 mg PF-04995274
- DRUG 1 mg PF-04995274
- DRUG 10 mg PF-04995274
- DRUG 15 mg PF-04995274
- DRUG 1.0 mg PF-04995274
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169714
The ClinicalTrials.gov registry entry for NCT01169714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 0.1 mg PF-04995274 is the first listed.
NCT01169714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01169714 about?
NCT01169714 is a clinical study titled "A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.". This study is designed to observe the safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 for a duration of 14 days, in healthy adult and healthy elderly.
What is the current status of trial NCT01169714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2010-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01169714?
The interventions under investigation include: 0.1 mg PF-04995274 (DRUG), 1 mg PF-04995274 (DRUG), 10 mg PF-04995274 (DRUG), 15 mg PF-04995274 (DRUG), 1.0 mg PF-04995274 (DRUG).
Who is sponsoring clinical trial NCT01169714?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.